MedPath

TherapeuticsMD

TherapeuticsMD logo
🇺🇸United States
Ownership
Public
Established
2008-01-01
Employees
1
Market Cap
$22.1M
Website
http://www.therapeuticsmd.com
Introduction

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Clinical Trials

6

Active:0
Completed:5

Trial Phases

3 Phases

Phase 1:2
Phase 2:1
Phase 3:3

Drug Approvals

1

FDA:1

Drug Approvals

ANNOVERA

Approval Date
Aug 23, 2022
FDA

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
3 (50.0%)
Phase 1
2 (33.3%)
Phase 2
1 (16.7%)

Annovera™ Drug-Drug Interaction Study

Phase 1
Completed
Conditions
Women
Contraception
Interventions
First Posted Date
2020-02-28
Last Posted Date
2021-01-29
Lead Sponsor
TherapeuticsMD
Target Recruit Count
67
Registration Number
NCT04290390
Locations
🇨🇦

Syneos Health, Quebec City, Quebec, Canada

The Effects of Annovera™ and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol

Phase 1
Completed
Conditions
Contraception
Interventions
First Posted Date
2020-02-17
Last Posted Date
2021-10-29
Lead Sponsor
TherapeuticsMD
Target Recruit Count
21
Registration Number
NCT04272008
Locations
🇺🇸

University of Pennsylvania Women's Health Clinical Research Center, Philadelphia, Pennsylvania, United States

🇨🇦

Syneos Health, Québec City, Quebec, Canada

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

Phase 2
Completed
Conditions
Menopause
Dyspareunia
Vulvovaginal Atrophy
Painful Intercourse
Interventions
Drug: placebo
First Posted Date
2015-05-20
Last Posted Date
2015-12-14
Lead Sponsor
TherapeuticsMD
Target Recruit Count
50
Registration Number
NCT02449902
Locations
🇺🇸

Avail Clinical Research, DeLand, Florida, United States

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

Phase 3
Completed
Conditions
Dyspareunia
Vulvovaginal Atrophy
Menopause
Painful Intercourse
Interventions
Drug: Placebo
First Posted Date
2014-10-01
Last Posted Date
2017-05-25
Lead Sponsor
TherapeuticsMD
Target Recruit Count
764
Registration Number
NCT02253173
Locations
🇺🇸

Medical Affiliated Research Center, Huntsville, Alabama, United States

🇺🇸

Montogomery Women's Health, Montgomery, Alabama, United States

🇺🇸

Cactus Clinical Research, Mesa, Arizona, United States

and more 98 locations

A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea

Phase 3
Terminated
Conditions
Secondary Amenorrhea
Interventions
Drug: Placebo
First Posted Date
2013-12-24
Last Posted Date
2018-05-08
Lead Sponsor
TherapeuticsMD
Target Recruit Count
6
Registration Number
NCT02019589
Locations
🇺🇸

Precision Trials/New Horizons Women's Care, Chandler, Arizona, United States

🇺🇸

Precision Clinical Trials/Arizona Wellness Center for Women, Phoenix, Arizona, United States

🇺🇸

Visions Clinical Research, Tucson, Arizona, United States

and more 18 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath